Hall SD - Search Results

1

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

Ayan-Oshodi MA, Willis BA, Annes WF, Lowe SL, Friedrich S, de la Peña A, Zhang W, Brown T, Wise SD, Hall SD. Ayan-Oshodi MA, et al. Among authors: hall sd. Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12. Drug Metab Dispos. 2012. PMID: 22789530 Clinical Trial.

2

An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

Mayhew BS, Jones DR, Hall SD. Mayhew BS, et al. Among authors: hall sd. Drug Metab Dispos. 2000 Sep;28(9):1031-7. Drug Metab Dispos. 2000. PMID: 10950845

3

Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin.

Asghar A, Gorski JC, Haehner-Daniels B, Hall SD. Asghar A, et al. Among authors: hall sd. Drug Metab Dispos. 2002 Jan;30(1):20-6. doi: 10.1124/dmd.30.1.20. Drug Metab Dispos. 2002. PMID: 11744607

4

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

Belle DJ, Callaghan JT, Gorski JC, Maya JF, Mousa O, Wrighton SA, Hall SD. Belle DJ, et al. Among authors: hall sd. Br J Clin Pharmacol. 2002 Jan;53(1):67-74. doi: 10.1046/j.0306-5251.2001.01521.x. Br J Clin Pharmacol. 2002. PMID: 11849197 Free PMC article.

5

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Williams JA, et al. Among authors: hall sd. Drug Metab Dispos. 2002 Aug;30(8):883-91. doi: 10.1124/dmd.30.8.883. Drug Metab Dispos. 2002. PMID: 12124305

6

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

Wang YH, Jones DR, Hall SD. Wang YH, et al. Among authors: hall sd. Drug Metab Dispos. 2004 Feb;32(2):259-66. doi: 10.1124/dmd.32.2.259. Drug Metab Dispos. 2004. PMID: 14744949

7

The effect of anesthesia and surgery on CYP3A activity in rats.

Uhing MR, Beno DW, Jiyamapa-Serna VA, Chen Y, Galinsky RE, Hall SD, Kimura RE. Uhing MR, et al. Among authors: hall sd. Drug Metab Dispos. 2004 Nov;32(11):1325-30. doi: 10.1124/dmd.104.000927. Epub 2004 Aug 19. Drug Metab Dispos. 2004. PMID: 15319324

8

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.

Wang YH, Jones DR, Hall SD. Wang YH, et al. Among authors: hall sd. Drug Metab Dispos. 2005 May;33(5):664-71. doi: 10.1124/dmd.104.001834. Epub 2005 Feb 2. Drug Metab Dispos. 2005. PMID: 15689501

9

Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.

Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Borges S, et al. Among authors: hall sd. Drug Metab Dispos. 2005 Jul;33(7):1052-5. doi: 10.1124/dmd.104.003459. Epub 2005 Apr 8. Drug Metab Dispos. 2005. PMID: 15821042

10

Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.

Chien JY, Lucksiri A, Ernest CS 2nd, Gorski JC, Wrighton SA, Hall SD. Chien JY, et al. Among authors: hall sd. Drug Metab Dispos. 2006 Jul;34(7):1208-19. doi: 10.1124/dmd.105.008730. Epub 2006 Apr 12. Drug Metab Dispos. 2006. PMID: 16611859

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters